UBS reconfirms purchases with Excellence despite a adjusted 2025 revenue outlook

Elevance Health, Inc. (NYSE:principle) rank between Best stocks to buy according to hedge funds. On June 17, UBS reaffirmed its bi-rating and $555 price target (NYSE: ELV), even after changing its revenue share for 2025. Elevance Health, Inc. (NYSE: ELV) initially predicted that first half revenue would account for 62-63% of the full year results. However, the company currently expects to account for 60%.

In order of importance, Elevance Health, Inc. (NYSE: ELV) identified three factors that influence second quarter revenue expectations. Basic clarity of the Affordable Care Act (ACA) population after membership erosion, out-of-network billing difficulties along exchange, and Medicaid costs do not slow down as quickly as expected.

To address these second quarter trends, Elevance Health, Inc. (NYSE: ELV) is considering ways to minimize costs to boost performance later this year.

Previously Anthem, Inc. Elevance Health, Inc. (NYSE:ELV) is the leading health benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability and behavioral health insurance across many brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon.

While acknowledging the potential of ELVs as an investment, we believe certain AI stocks offer a greater reverse chance, pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

read more: 10 Best Magic Formula Stocks of 2025 and Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.